Protein (2)
Launched (2)
Human (1)Mouse (1)
His Tag (2)
Unconjugated (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
LEN-H52H3 | HEK293 | Human Legumain Protein, His Tag (Pro-form) | ![]() | |||
LEN-M52H3 | HEK293 | Mouse Legumain Protein, His Tag (Pro-form, HPLC verified) | ![]() |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mouse nerve growth factor (Sinobioway Biomedicine) | Phase 3 Clinical | Sinobioway Biomedicine Co Ltd | Diabetic Foot; Optic Nerve Injuries | Details | |
| Choroid plexus cell replacement therapy (Living Cell Technologies) | Phase 3 Clinical | Living Cell Technologies | Surgical Wound Infection | Details | |
| Recombinant human nerve growth factor (Sichuan ZehaTimes Pharmaceutical) | Phase 2 Clinical | Sichuan ZehaTimes Pharmaceutical Co Ltd | Optic Nerve Injuries | Details | |
| Recombinant human nerve growth factor(Sinobioway Biomedicine) | SMR001; SMR-001 | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Xerophthalmia | Details |
| Recombinant human nerve growth factor (Xintrum Pharmacouticals) | rh-NGF | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Keratitis; Optic Nerve Injuries; Glaucoma, Open-Angle | Details |
| CHF-6467 | CHF-6467 | Phase 2 Clinical | Chiesi Farmaceutici SPA | Diabetic Foot | Details |
| Udonitrectag | REC-0559; MT-8; REC 0/0559 | Phase 2 Clinical | Mimetech SRL | Keratitis | Details |
| Recombinant human nerve growth factor(Chongqing Kerun Biologic) | Phase 1 Clinical | Keratitis | Details | ||
| CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
| Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
| Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cenegermin | rhNGF (Dompe Farmaceutici) | Approved | Dompe Farmaceutici Spa | 欧适维, Sentinel, Oxervate | EU | Keratitis | Dompé Pharmaceutici Spa | 2017-07-06 | Keratitis; Corneal Ulcer; Corneal Diseases; Dry Eye Syndromes; Retinitis Pigmentosa; Eye Diseases; Nervous System Diseases | Details |
| Mouse nerve growth factor (Wuhan Hiteck Bio-pharmaceutical) | Approved | Wuhan Hiteck Biological Pharma Co Ltd | 金路捷 | Mainland China | Trauma, Nervous System | Wuhan Hiteck Biological Pharma Co Ltd | 2002-01-01 | Optic Nerve Injuries; Trauma, Nervous System | Details | |
| Mouse nerve growth factor (Livzon Group) | Approved | Livzon Pharmaceutical Group Inc | 丽康乐 | Mainland China | Optic Nerve Injuries | Livzon(Group) Pharmaceutical Factory | 2010-05-07 | Optic Nerve Injuries | Details | |
| Mouse nerve growth factor (Staidson Biopharma) | Approved | 苏肽生 | Mainland China | Optic Nerve Injuries | Staidson(Beijing) Biopharmaceuticals Co Ltd | 2006-04-11 | Diabetic Foot; Optic Nerve Injuries; Peripheral Nerve Injuries | Details |






